{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:38:12Z","timestamp":1792165092664,"version":"4.4.0"},"reference-count":27,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background: With rising obesity rates, pharmacological interventions are increasingly used in non-diabetic adults. While being effective in managing weight, these agents frequently cause gastrointestinal (GI) side effects, affecting adherence and long-term outcomes. Objective: To systematically evaluate the frequency, severity, and types of GI adverse effects (AEs) associated with anti-obesity medications in obese adults without diabetes. Methods: Following PRISMA 2020 guidelines, PubMed, Google Scholar, BMJ, and Web of Science were searched (last search July 2025). Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, cross-sectional, and case\u2013control studies. Only reports of GI AEs in non-diabetic adults were included. Risk of bias was assessed using Cochrane RoB 2 and Newcastle\u2013Ottawa scales. Results: Out of 733 articles screened, 12 studies met predefined inclusion criteria, including one large cohort of 18,386 participants, along with randomized and observational trials of smaller size. The most frequently reported GI symptoms were nausea, vomiting, diarrhea, and constipation, predominantly with GLP-1 receptor agonists such as semaglutide and tirzepatide, especially during dose escalation. Orlistat commonly linked to steatorrhea and flatulence, while phentermine was associated with reduced GI motility. Newer agents, including retatrutide and orforglipron, also demonstrated notable GI side effect profiles. Natural products and investigational agents reported fewer adverse events but lacked long-term data and standardized reporting. Limitations: Evidence was limited by heterogeneity in study design and inconsistent reporting of GI outcomes. Conclusion: GI side effects are common across anti-obesity medications, particularly GLP-1 receptor agonists. Although generally mild to moderate, these symptoms can impact adherence and lead to treatment discontinuation. Tailored titration schedules, proactive patient counseling, and standardized adverse event reporting may improve tolerability. Further research is warranted to evaluate long-term GI outcomes and compare safety across emerging pharmacologic agents.<\/jats:p>","DOI":"10.3390\/medicina61111987","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:09:47Z","timestamp":1762358987000},"page":"1987","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9062-9761","authenticated-orcid":false,"given":"Ehab","family":"Takrori","sequence":"first","affiliation":[{"name":"College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-9474","authenticated-orcid":false,"given":"Supriya","family":"Peshin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Norton Community Hospital, Norton, VA 24273, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Singal","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, East Tennessee State University, Johnson City, TN 37614, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2023). Obesity and Overweight, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100018","DOI":"10.1016\/j.obpill.2022.100018","article-title":"Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","volume":"2","author":"Bays","year":"2022","journal-title":"Obes. Pillars"},{"key":"ref_3","first-page":"539","article-title":"Three- and six-month efficacy and safety of phentermine in a Mexican obese population","volume":"59","year":"2025","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity\u2014A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.7570\/jomes23032","article-title":"Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon","volume":"32","author":"Jeon","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rodgers, M., Migdal, A.L., Rodr\u00edguez, T.G., Chen, Z.-Z., Nath, A.K., Gerszten, R.E., Kasid, N., Toschi, E., Tripaldi, J., and Heineman, B. (2021). Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.742873"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bandala, C., Carro-Rodr\u00edguez, J., C\u00e1rdenas-Rodr\u00edguez, N., Pe\u00f1a-Montero, I., G\u00f3mez-L\u00f3pez, M., Hern\u00e1ndez-Rold\u00e1n, A.P., Huerta-Cruz, J.C., Mu\u00f1oz-Gonz\u00e1lez, F., Ignacio-Mej\u00eda, I., and Dom\u00ednguez, B. (2024). Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. Nutrients, 16.","DOI":"10.3390\/nu16142284"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e13744","DOI":"10.1111\/cts.13744","article-title":"Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects","volume":"17","author":"Won","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40261-024-01418-3","article-title":"Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity","volume":"45","author":"Ishibashi","year":"2025","journal-title":"Clin. Drug Investig."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Valero-P\u00e9rez, M., Bermejo, L.M., L\u00f3pez-Plaza, B., Garc\u00eda, M.A., Palma-Milla, S., and G\u00f3mez-Candela, C. (2020). Regular Consumption of Lipigo\u00ae Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program. Nutrients, 12.","DOI":"10.3390\/nu12071960"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cabrera-Rode, E., Cubas-Due\u00f1as, I., Acosta, J.R., Hern\u00e1ndez, J.C., Gonz\u00e1lez, A.I.C., Calero, T.M.G., Dom\u00ednguez, Y.A., Rodr\u00edguez, J.H., Rodr\u00edguez, A.D.R., and \u00c1lvarez \u00c1lvarez, A. (2023). Efficacy and safety of Obex\u00ae in overweight and obese subjects: A randomised, double-blind, placebo-controlled clinical trial. BMC Complement. Med. Ther., 23.","DOI":"10.1186\/s12906-023-03847-7"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ponce Mart\u00ednez, C., Murcia Garc\u00eda, E., P\u00e9rez S\u00e1nchez, H., Milagro, F.I., Riezu-Boj, J.I., Ramos Molina, B., G\u00f3mez Gallego, M., Zamora, S., Ca\u00f1avate Cutillas, R., and Hern\u00e1ndez Morante, J.J. (2024). Effect of Silibinin on Human Pancreatic Lipase Inhibition and Gut Microbiota in Healthy Volunteers: A Randomized Controlled Trial. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202410.1784.v1"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Sayed, U.F.S.M., Moshawih, S., Goh, H.P., Kifli, N., Gupta, G., Singh, S.K., Chellappan, D.K., Dua, K., Hermansyah, A., and Ser, H.L. (2023). Natural products as novel anti-obesity agents: Insights into mechanisms of action and potential for therapeutic management. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1182937"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: A systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int. J. Obes."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Liu, S., Hu, J., Zhao, C., Liu, H., and He, C. (2025). Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with\/without type 2 diabetes: A systematic review and network meta-analysis. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1513641"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat. Med."},{"key":"ref_27","first-page":"305","article-title":"Pharmacotherapy for Obesity: Recent Updates","volume":"17","author":"Fredrick","year":"2025","journal-title":"Clin. Pharmacol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1987\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:39:48Z","timestamp":1762360788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111987"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111987","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}